Hubungan Antara Kadar Homosistein Serum Dengan Skor Vitiligo Area Scoring Index pada Pasien Vitiligo
61
DAFTAR PUSTAKA
1. Mateen A, Syed R, Alharbi KK, Khan IA. An Overview of Quality of Life
in Vitiligo Patients – At Glance. Pigmentary Disorders S3: 003.2005.
doi:10.4172/2376-0427.S3-003.
2. Ramakrishna P, Rajni T .Psychiatric Morbidity and Quality of Life in
Vitiligo Patients.Indian J Psychol Med. 2014 Jul-Sep; 36(3): 302–3. doi:
10.4103/0253-7176.135385
3. Alikhan A, Felsten LM, Daly M, Petronic-Rosic V. Vitiligo: A
comprehensive overview part I. Introduction, epidemiology, quality of life,
diagnosis, differential diagnosis, associations, histopathology, etiology, and
work-up. J Am Acad Dermatol [Internet] 2011[ cited 2015 Nov 25];65:47391. Available from:http://www.ncbi.nlm.nih.gov/ pubmed/ 21839315.
4. Jusuf NK, Meher C. Pola Kelainan Pigmentasi di Poliklinik Kulit dan
Kelamin Divisi Kosmetik RSUP H. Adam Malik Medan Tahun 20122015.
Pertemuan Ilmiah Tahunan XV Ilmu Kesehatan Kulit dan Kelamin. Padang,
Indonesia.
5. Rizal Y, Lestari S. Insidensi vitiligo di poliklinik kulit dan kelamin RSUP
Dr. M Djamil Padang tahun 2001-2006. MDVI [Internet]. 2008 [cited 2015
Nov 26]; Januari 35 (1): 77. Available from: http://www.perdoski.org
/index.php /public /information /mdvi-detail-content/77
6. Birlea SA, Spritz RA, Noris DA. Vitiligo. In: Goldsmith LA, Katz SI,
Gilchrest BA, Paller AS, Leffel DJ, Wolff K,editors.
Fitzpatrick's
th
dermatology in general medicine. 8 ed. New York: The MCGraw-Hill
companies. 2012. p. 1308-24.
7. Sehgal VN, Srivastava G. Vitiligo: Compendium of clinicoepidemiological features. Indian J Dermatol Venereol Leprol. 2007;73:14956.
8. Yaghoobi R, Omidian M, Bagherani N. Vitiligo: A review of the published
work. Journal of Dermatology. 2011;38:419-31. doi: 10.111 1/j.13468138.2010.01139.x.
9. Karadag AS, Tutal E, Ertugrul DT, Akint KO, Bilgili SG. Serum
holotranscobalamine, vitamin B12, folic acid and homocysteine levels in
patients with vitiligo. Clin Exp Dermatol. 2011 April; 37: 62-4.
doi:10.1111/j. 1365-2230.2011.04142.x.
10. Bolander-Gouaille C. Homocysteine, the new marker of disease riskan overview. Business briefing: European pharmacotherapy. 2005;2-8.
doi:10.1.1.199.9952.
11. Selhub J. Homocysteine metabolism. Annu. Rev Nutr. 1999; 19:217-46.
doi:0199-9885/99/0715-0217$08.00.
12. Clarke
S,
Banfield
K.
S-Adenosylmethionine-dependent
methyltransferases.In: Carmel R, Jacobsen DW, editors. Homocysteine in
health and disease. Cambridge. Cambridge university press; 2001.p. 63-78
13. Agarwal S, Mendiratta V, Chander R, Jain A, Yadav P. Study of serum
levels of Vitamin B, folic acid, and homocysteine in vitiligo. Pigment Int
2015;2:76-80. doi: 10.4103/2349-5847.172777
14. Juhlin L, Olsson MJ. Improvement of vitiligo after oral treatment with
vitamin B12 and folic acid and the importance of sun exposure. Acta Derm
Venereol. 1997; 77:460-2. doi:0001-5555.
Universitas Sumatera Utara
62
15. Don P, Iuga A, Dacko A, Hardick K. Treatment of vitiligo with broadband
ultraviolet B and vitamins. Int J Dermatol [Internet]. 2006 [ cited 2015 Nov
28] ; 45:63-5. Available from: http://www.ncbi. nlm.nih. gov/pubmed/
16426381
16. Dicle O (2015) Assessment Methods in Vitiligo. Pigmentary Disorders
2:160. doi:10.4172/2376-0427.1000160
17. Alghamdi KM, Kumar A,Taieb A, Ezzedine K. Assessment methods for
the evaluation of vitiligo.JEADV.2012. doi: 10.1111/j.1468-3083.2012.040
5.x
18. Vrijman C, Homan MWL, Limpens J, Veen WVD, Wolkerstorfer AW,
Terwee CB, et al. Measurement properties of outcome measures for
vitiligo. Arch Dermatol [Internet]. 2012 [cited 2015 Nov 28]; 148(11):
1302-9.Available from:http://www.ncbi.nlm.nih.gov/pubmed/ 22986764.
19. Sabry HH, Sabry JH, Hashim HM. Serum levels of homocysteine, vitamin
B12, and folic acid in vitiligo. Egypt J Dermatol Venerol [Internet] 2014
[cited
2015
Nov
29];34:65-9.
Available
from:
http://www.ejdv.eg.net/text.asp?2014/34/l/65/137315.
20. Singh S, Singh U, Pandey SS. Serum folic acid, vitamin B12 and
homocysteine levels in Indian vitiligo patients. EDOJ [ Internet]. 2012 June
[ cited 2015 Nov 29]; 8(1):1-7. Available from: http :// www. edoj.
org.eg/vol008/0801/002/01.htm.
21. Shaker OG, El-Tahlawi SMR. Is there a relationship between homocysteine
and vitiligo? A pilot study. BJD. 2008; 159: 720-4. doi: 10.1111/J.13652133.2008.08712.X.
22. Zaki AM, Abdo HM, Ibrahim IM, Ibrahim AEKI. Serum homocysteine and
vitiligo. The gulf journal of dermatology and venereology[Internet]. 2014[
cited 2015 Nov 29] ; 21(2): 15-20.Availble from: https://www.google.
com/url?sa=t&rct=j&q=&esrc =s& source=web&cd=3&ved= 0ahUKE
wjzy8p1cnKAhVBBY4KHQnjB1EQFggrMAI&url=http%3A%2F%2Fww
w.gulfdermajournal.com%2Fpdf%2F2014-10%2F2.pdf&usg=AFQjCN GX
yvhhvl6trAe0SHRVAImXn0Yi1g&sig2=5MUvJNMVGIU_eS1rBkBO7A
&cad=rja
23. Yasar A, Gunduz K, Onur E, Calkan M. Serum homocysteine, vitamin
B12, folic acid levels and methylenetetrahydrofolate reductase (MTHFR)
gene polymorphism in vitiligo. Disease markers. 2012; 33: 85-9. Doi:
10.3233/DMA-2012-0908.
24. Ghalamkarpour F Jafarian Z, Einollahi H, Younespour S. Homocysteine: is
it a biomarker for vitiligo? Journal of pigmentary disorders. 2015; 2(4): 1-4.
doi: 10.4172/2376-0427.1000172
25. Silverberg JI, Silverberg NB. Serum homocysteine as a biomarker of
vitiligo vulgaris severity: A pilot study. J Am Acad Dermatbl. 2011. 64(2):
445-7. doi: 10.1016/j,jaad.2010.08.025.
26. Rahman MH, Amin MZ, Rahman M, Satter MA. A demographic study
on vitiligo (sheti) in Bangladesh. Int J Res Med Sci. 2013; 1(2):123-8. doi:
10.5455/2320-6012.ijrms20130517.
27. Puri N, Phil M, Mojamdar M, Ramaiah A. In vitro growth characteristics of
melanocytes obtained from adult normal and vitiligo subjects.The journal
Universitas Sumatera Utara
63
of investigative dermatology. 1987; 88(4): 434-8. doi: 0022-202X/
87/$03.50.
28. Spritz RA. Six decades of vitiligo genetics: genome-wide studies provide
insights into autoimmune pathogenesis. J Invest Dermatol. 2012;132: 26873. doi: 10.1038/jid.2011.321.
29. Baum S, Barzilai A, Trau H. Vitiligo. In : Shoenfeld Y, Cervera R,
Gershwin ME, editors. Diagnostic criteria in autoimmune diseases.
Humana press [Internet]. 2008 [cited 2015 Dec 3].p. 353-8. Available from:
http://link.springer.com/ book/ 10.1007%2F978-l-60327-285-8
30. Bowcock AM, Fernandez-Vina M. Targeting skin: vitiligo and autoimm
unity. J Invest Dermatol. 2012; 132: 13-5. doi:10.103S /jid.201 1.353.
31. Wang CQF, Cruz-Inigo AE, Fuentes-Duculan J, Moussai D, Gulati N. Thl7
cells and activated dendritic cells are increased in vitiligo lesions. PLoS
One. 2011 April; 6(4): 1-11. doi: 10.1371/journal.pone.0018907
32. Rezaei N, Gavalas NG, Weetman AP, Kemp EH. Autoimmunity as an
aetiological factor in vitiligo. J Eur Acad Dermatol Venereol. 2007; 21:
865-876.doi: 10.1111/J.1468-3083.2007.02228.X.
33. Kemp EH, Emhemad S, Gawkrodger DJ, Weetman AP. Autoimmune
disorders-pathogenic aspects. Chapter 14. p. 255-78. doi: 10.5772/802
34. Haider N, Islam MS, Al-Maraf A, Shohag MH, Ali R, Rahman GKMM,
Hasnat A. Oxidative stress and antioxidant status in vitiligo patients. Dhaka
Univ J Pharm Sci. 2010 Dec; 9(2): 103-8. doi: 10.3329/dujps.v9i2.7894.
35. Naini FF, Shooshtari AV, Ebrahimi B, Molaei R. The effect of
pseudocatalase/superoxide dismutase in the treatment of vitiligo: a pilot
study. J Res Pharm Pract 2012; 1:77-80. doi: 10.4 103/2279-042X. 108375.
36. Shin JW, Nam KM, Choi HR, Huh SY, Kirn SW, Youn SW, et al.
Erythrocyte malondialdehyde and glutathione levels in vitiligo patients.
Ann Dermatol. 2010; 22(3): 279-83. doi: 10.5021/ad.2010.22.3.279.
37. Amin MZ, Rahman MH, Satter MA. Study of some biochemical
parameters of vitiligo patients in Bangladesh. Bangladesh J Sci Ind Res [
Internet]. 2012 [ cited
2015 Dec 10]; 47(2): 173-86. Available from: .
http://www.banglajol.info/index.php/BJSIR /article/view II 1449.
38. Esmaeili B, Rezaee SAR, Layegh P, Afshari JT, Dye P, Karimiani EG, et al
Expression of IL-17 and COX2 gene in peripheral blood leukocytes of
vitiligo patients. Iran J Allergy Asthma Immunol [Internet]. 2011 [cited
2015 Dec 11]; 10(2):81-9. Available from: http://www.sid.ir
/en/VEWSSID/J_pdf/943201 10202.pdf.
39. Glassman SJ. Vitiligo, reactive oxygen species and T-cells. Clin Sci. 2011;
120: 99-120.doi: 10.1042/CS20090603.
40. Kamel N, Sobhy N, Kamal H, Ismail M. A comparative study of oxidantantioxidant status in blood and tissue in vitiligo patients. EDOJ [Internet].
2010
[cited
2015 Dec 11] ;
6(2):
1-10. Available from:
http://www.edoj.org.eg/vol006/0602/002/paper.pd
Universitas Sumatera Utara
64
41. Ezzedine K, Lifn HW, Suzuki T, Katayama I, Hamzavi I, Lan CCE, et
al.Revised classification/nomenclature of vitiligo and related issues: the
vitiligo global issues consensus conference . Pigment Cell Melanoma Res.
2012 May; 25(3): El-13. doi:10.1111/j.l755-148X.2012.00997.x.
42. Faria AR, Mira MT, Tarle RG, Castro CCS, Dellatore G. Vitiligo-part2
classification, histopathology and treatment. An Bras Dermatol.
2014;89(5):784-90.doi: 10.1590/abdl806-4841.20142717.
43. Taieb A, Alomar A, Bohm M, Dell'Anna ML, PAse D, Eleftheriadou V, et
al. Guidelines for the management of vitiligo: the European dermatology
forum concencus. BJD. 2012 July; 168:5-19. doi:10.1111/j.l3652133.2012.11197.x.
44. Brazelli V, Antoninetti M, Palazzini S, Barbagallo T, De Silvestri A,
Borroni G. Critical evaluation of the variants influencing the clinical
response of vitiligo: study of 60 cases treated with ultraviolet B narrow
band phototherapy. J Eur Acad Dermatol Venereol. 2007;21:1369-74. doi:
10.1111/j.1468-3083.2007.02278.x.
45. Taieb A, Morice-Picard F, Jouary T, Ezzedine K, Cario^Andre M, Gauthier
Y. Segmental vitiligo as the possible expression of cutaneous somatic
mosaicism: implications for common non-segmental vitiligo. Pigment Cell
Melanoma Res. 2008; 21:646-52. doi: 10.1111/j. 1755-148X.2008.00511.x.
46. Hann S, Chang J, Lee H, Kim S. The classification of segmental vitiligo on
the face. Yonsei Med J [Internet]. 2000 [ cited 2015 Dec 12]; 41(2): 20912. Available from:http://www.ncbi.nlm.nih.gov/pubmed/10817021.
47. Bhor U, Pande S. Scoring systems in dermatology. Indian J Dermatol
Venereol Leprol [serial online] 2006 [cited 2015 Dec 13];72:315-21.
Available from: http://www.ijdvl. com/text.asp?2006/72/4/315/26722.
48. Taieb A, Picardo M. The definition and assessment of vitiligo: a
consensus report of the Vitiligo European Task Force. Pigment Cell
Res.2007; 20:27-35. doi: 10.1111/j.1600-0749.2006.00355.
49. Kawakami T, Hashimoto T. Disease severity indexes and treatment
evaluation criteria in vitiligo. Dermatol Res Pract. 2011; 1-3. doi: 10.1155
72011/750342.
50. Hamzavi I, Hain H, McLean D, Shapiro J, Zeng H, Lui H. Parametric
modeling of narrowband UVB phototherapy for vitiligo using a novel
quantitative
tool
the
vitiligo
area
scoring
index.
Arch
Deermatol.2004;140:677-83.
51. Al-mutairi N, Nour-Eldin O. Vitiligo treatment update. GJDV [Internet].
2003 Oct [cited 2015 Dec 14] ;10 (2): 1-13. Available from: http://www.
gulfdermaj ournal. com/pdf/2003 -10/1 .pdf.
52. Bordere AC, Lambert J, Geel NV. Current and emerging therapy for the
management of vitiligo. Clin Cosmet Investig Dermatol [Internet].
2009[cited 2015 Dec 14] ; 2: 15-25. Available from: http://www. ncbi .nlm.
nih.gov/pmc/articles/PMC3047938/.
Universitas Sumatera Utara
65
53.Felsten
L,
Alikhan
A,
Petronic-Rosic
V.
Vitiligo:A
comprehensive overview part II: Treatment options and approach to
treatment. J Am Acad Dermatol [Internet]. 2011[ cited 2015 Dec
16];65:493-514.
Available from: http://www .ncbi.nlm.
nih.gov/pubmed/21839316.
54.Gawkrodger DJ, Omerod AD, Shaw L, Mauri-sole I, Whitton ME,
Watts MJ, et al.Guideline for the diagnosis and management of vitiligo.
BJD.2008; 159: 1051-76. doi: 10.1111/j.1365-2133.2008. 08881.x
55.Clarke R. Lowering blood homocysteine with folic acid
base supplements: meta-analysis of
randomised
trials.
BMJ
[Internet].1998[cited 2015 Dec 17]; 894-8. Available from:
http://www. ncbi.nlm.nih.gov/pmc/articles/PMC28491/pdt7894.pdf.
56.Andre's E, Loukili NH, Noel E, Kaltenbach G, Abdelgheni MB, Perrin
AE, et al. Vitamin B12 (cobalamin) deficiency in elderly patients. CMAJ
[Internet]. 2004 [cited 2015 Dec 17] ; 17(3): 251-9.
Availablefrom:http://www.researchgate.net/profile/Frederic_Maloisel/publi
cation/8421627_Vitamin_B12_(cobalamin)_deficiency_in_elderly_pa
tients/links/OOb49 52289e7cc6179000000.pdf.
57.Hustad S, Ueland PM, Vollset SE, Zhang Y, Bj0rke-Monsen AL,
Schneede J. Riboflavin as a determinant of plasma total homocysteine:
effect modification by the rnethylenetetrahydrofolate reductase C677T
polymorphism. Clin Chem [ Internet]. 2000 [ cited 2015 Dec 18]; May 46
(8):
1065-71.
Available
from:
http://www
.clinchem
.
org/content/46/8/1065. Long.
58.Ubbink JB, Vermaak WJH, Merwe AVD, Becker PJ. Vitamin B12,vitamin b-6,
and
folate
nutritional
status
in
men
withhyperhomocysteinemia. Am J Clin Nutr [Internet]. 1993 [ cited 2015
Dec 19] ; 57: 47-53. Availabe from: http://ajcn. nutrition, org/
content'/57/l/47.1ong.
59. Bailey LB, Gregory JF. Folate metabolism and requirements. J. Nutr
[Internet]. 1999 [cited 2015 Dec 19]; 129: 779-82. Available from:
http://jn.nutrition.org /content/129/ 4/779. full.pdf+html.
60.Balci DD, Yunden Z, Yenin JZ, Okumus N. Serum homocysteine,
folic acid and vitamin B12 levels in vitiligo. EJD. 2009 Jul-Aug; 19 (4):
382-3. doi:10.1684/ejd.2009.0671.
61.Becatti M, Prigano F, Fiorillo, Pescitelli L, Nassi P, Lotti T, Taddei
N.The involvement of Smac/DIABLO, p53,NF-kB, and MAPK pathways
in apoptosis of keratinocytes from perilesional vitiligft skin: protective
effects of curcumin and capsaicin. Antioxidants & Redox Signaling.
2010; 13(9):1309-21. doi: 10.1089/ars.2009.2779.
62.Yu H, Chang K, Yu C, Li H, Wu M, Wu C,et al. Alterations in IL-6, IL-8,
GM-CSF, TNF-a, and IFNy release by peripheral mononuclear cells in
patients with active vitiligo. J invest Dermatol. 1997.108: 527 -9.
doi: 10.111 l/1523-1747.ep12289743.
Universitas Sumatera Utara
66
63. Utama A. Gambaran penyakit vitiligo di RSUP Haji Adam Malik Medan
tahun 2012-2014. S.Ked [Skripsi]. Medan: Universitas Sumatera Utara;
2015.
64. Rahmayanti ND, Rahmadewi. Studi Retrospektif: Profil Pasien Baru
Vitiligo
(A Retrospective Study: The Profile of New Patient with
Vitiligo). Berkala Ilmu Kesehatan Kulit dan Kelamin – Periodical of
Dermatology and Venereology. 2016 Aug; 28(2):52-8. doi:
10.20473/bikkk.V28.2.2016.52-58.
65. El-Dawela RE, Abou-elfetouh S. Relationship between homocysteine,
vitamin B12, folic acid levels and vitiligo. J. Appl. Sci. Res .2012; 8(11):
5528-35.
66. Silverberg NB. The Epidemiology of Vitiligo. Curr Derm Rep. 2015 Jan;
4:36–43.doi: 10.1007/s13671-014-0098-6.
67. Jha BN. Assessment of Prevalence of Clinical and Sociodemographic
Study of Vitiligo in Janaki Medical College, Nepal. 2016 Feb;ARJLS.
2(2):1 – 4. ISSN: 2455-3549.
68. Patil S, Gautam M, Nadkarni N, Saboo N, Godse K, Setia MS. Gender
Differences in Clinicoepidemiological Features of Vitiligo: A
CrossSectional Analysis. ISRN Dermatology. 2014 Feb;1-6. doi:
10.1155/2014/186197.
69. Elhuda. Hubungan kadar homosistei serum dengan skor vitiligo area
scoring index (VASI) . Sp.DV [ Tesis]. Padang: Universitas Andalas;
2016.
70. Battezati A, Bertoli S, Romerio AS, Testolin G. Body composition: An
important determinant of homocysteine and methionine concentrations in
healthy individuals. NMCD. 2007 Sept; 17(7): 525–34. doi:10.1016/j.num
ecd. 2006.03.006.
71. Dimitrova KR, DeGroot K, Myers AK, Kim YD. Estrogen and
homocysteine. Cardiovacres. 2002 Feb; 53:577-88. doi: 10.1016/S00086363(01)00462-X 577-588.
72. Alomari MA, Khabour OF, Gharaibeh MY, Qhatan RA .Effect of physical
activity on levels of homocysteine, folate, and vitamin B12 in the elderly.
Phys Sportsmed. 2016 Feb; 44(1):68-73. doi: 10.1080/00913847.2016.113
5037.
73. Koehler KM, Baum RG, Gary PJ, Allen RH, Stabler SP, Rimm EB.
Association of folate intake and serum homocysteine in elderly persons
according to vitamin supplementation and alcohol use. Am J Clin Nutr.
2001 March ; 73:628–37. PMID:11237942.
74. Qureshi SS, Gupta SK, Upmanyu N. A review on hyperhomocysteinemia
and its risk factors. Innovare Journal of Medical Science. 2016; 4( 2): 114. ISSN: 2321-4406.
Universitas Sumatera Utara
DAFTAR PUSTAKA
1. Mateen A, Syed R, Alharbi KK, Khan IA. An Overview of Quality of Life
in Vitiligo Patients – At Glance. Pigmentary Disorders S3: 003.2005.
doi:10.4172/2376-0427.S3-003.
2. Ramakrishna P, Rajni T .Psychiatric Morbidity and Quality of Life in
Vitiligo Patients.Indian J Psychol Med. 2014 Jul-Sep; 36(3): 302–3. doi:
10.4103/0253-7176.135385
3. Alikhan A, Felsten LM, Daly M, Petronic-Rosic V. Vitiligo: A
comprehensive overview part I. Introduction, epidemiology, quality of life,
diagnosis, differential diagnosis, associations, histopathology, etiology, and
work-up. J Am Acad Dermatol [Internet] 2011[ cited 2015 Nov 25];65:47391. Available from:http://www.ncbi.nlm.nih.gov/ pubmed/ 21839315.
4. Jusuf NK, Meher C. Pola Kelainan Pigmentasi di Poliklinik Kulit dan
Kelamin Divisi Kosmetik RSUP H. Adam Malik Medan Tahun 20122015.
Pertemuan Ilmiah Tahunan XV Ilmu Kesehatan Kulit dan Kelamin. Padang,
Indonesia.
5. Rizal Y, Lestari S. Insidensi vitiligo di poliklinik kulit dan kelamin RSUP
Dr. M Djamil Padang tahun 2001-2006. MDVI [Internet]. 2008 [cited 2015
Nov 26]; Januari 35 (1): 77. Available from: http://www.perdoski.org
/index.php /public /information /mdvi-detail-content/77
6. Birlea SA, Spritz RA, Noris DA. Vitiligo. In: Goldsmith LA, Katz SI,
Gilchrest BA, Paller AS, Leffel DJ, Wolff K,editors.
Fitzpatrick's
th
dermatology in general medicine. 8 ed. New York: The MCGraw-Hill
companies. 2012. p. 1308-24.
7. Sehgal VN, Srivastava G. Vitiligo: Compendium of clinicoepidemiological features. Indian J Dermatol Venereol Leprol. 2007;73:14956.
8. Yaghoobi R, Omidian M, Bagherani N. Vitiligo: A review of the published
work. Journal of Dermatology. 2011;38:419-31. doi: 10.111 1/j.13468138.2010.01139.x.
9. Karadag AS, Tutal E, Ertugrul DT, Akint KO, Bilgili SG. Serum
holotranscobalamine, vitamin B12, folic acid and homocysteine levels in
patients with vitiligo. Clin Exp Dermatol. 2011 April; 37: 62-4.
doi:10.1111/j. 1365-2230.2011.04142.x.
10. Bolander-Gouaille C. Homocysteine, the new marker of disease riskan overview. Business briefing: European pharmacotherapy. 2005;2-8.
doi:10.1.1.199.9952.
11. Selhub J. Homocysteine metabolism. Annu. Rev Nutr. 1999; 19:217-46.
doi:0199-9885/99/0715-0217$08.00.
12. Clarke
S,
Banfield
K.
S-Adenosylmethionine-dependent
methyltransferases.In: Carmel R, Jacobsen DW, editors. Homocysteine in
health and disease. Cambridge. Cambridge university press; 2001.p. 63-78
13. Agarwal S, Mendiratta V, Chander R, Jain A, Yadav P. Study of serum
levels of Vitamin B, folic acid, and homocysteine in vitiligo. Pigment Int
2015;2:76-80. doi: 10.4103/2349-5847.172777
14. Juhlin L, Olsson MJ. Improvement of vitiligo after oral treatment with
vitamin B12 and folic acid and the importance of sun exposure. Acta Derm
Venereol. 1997; 77:460-2. doi:0001-5555.
Universitas Sumatera Utara
62
15. Don P, Iuga A, Dacko A, Hardick K. Treatment of vitiligo with broadband
ultraviolet B and vitamins. Int J Dermatol [Internet]. 2006 [ cited 2015 Nov
28] ; 45:63-5. Available from: http://www.ncbi. nlm.nih. gov/pubmed/
16426381
16. Dicle O (2015) Assessment Methods in Vitiligo. Pigmentary Disorders
2:160. doi:10.4172/2376-0427.1000160
17. Alghamdi KM, Kumar A,Taieb A, Ezzedine K. Assessment methods for
the evaluation of vitiligo.JEADV.2012. doi: 10.1111/j.1468-3083.2012.040
5.x
18. Vrijman C, Homan MWL, Limpens J, Veen WVD, Wolkerstorfer AW,
Terwee CB, et al. Measurement properties of outcome measures for
vitiligo. Arch Dermatol [Internet]. 2012 [cited 2015 Nov 28]; 148(11):
1302-9.Available from:http://www.ncbi.nlm.nih.gov/pubmed/ 22986764.
19. Sabry HH, Sabry JH, Hashim HM. Serum levels of homocysteine, vitamin
B12, and folic acid in vitiligo. Egypt J Dermatol Venerol [Internet] 2014
[cited
2015
Nov
29];34:65-9.
Available
from:
http://www.ejdv.eg.net/text.asp?2014/34/l/65/137315.
20. Singh S, Singh U, Pandey SS. Serum folic acid, vitamin B12 and
homocysteine levels in Indian vitiligo patients. EDOJ [ Internet]. 2012 June
[ cited 2015 Nov 29]; 8(1):1-7. Available from: http :// www. edoj.
org.eg/vol008/0801/002/01.htm.
21. Shaker OG, El-Tahlawi SMR. Is there a relationship between homocysteine
and vitiligo? A pilot study. BJD. 2008; 159: 720-4. doi: 10.1111/J.13652133.2008.08712.X.
22. Zaki AM, Abdo HM, Ibrahim IM, Ibrahim AEKI. Serum homocysteine and
vitiligo. The gulf journal of dermatology and venereology[Internet]. 2014[
cited 2015 Nov 29] ; 21(2): 15-20.Availble from: https://www.google.
com/url?sa=t&rct=j&q=&esrc =s& source=web&cd=3&ved= 0ahUKE
wjzy8p1cnKAhVBBY4KHQnjB1EQFggrMAI&url=http%3A%2F%2Fww
w.gulfdermajournal.com%2Fpdf%2F2014-10%2F2.pdf&usg=AFQjCN GX
yvhhvl6trAe0SHRVAImXn0Yi1g&sig2=5MUvJNMVGIU_eS1rBkBO7A
&cad=rja
23. Yasar A, Gunduz K, Onur E, Calkan M. Serum homocysteine, vitamin
B12, folic acid levels and methylenetetrahydrofolate reductase (MTHFR)
gene polymorphism in vitiligo. Disease markers. 2012; 33: 85-9. Doi:
10.3233/DMA-2012-0908.
24. Ghalamkarpour F Jafarian Z, Einollahi H, Younespour S. Homocysteine: is
it a biomarker for vitiligo? Journal of pigmentary disorders. 2015; 2(4): 1-4.
doi: 10.4172/2376-0427.1000172
25. Silverberg JI, Silverberg NB. Serum homocysteine as a biomarker of
vitiligo vulgaris severity: A pilot study. J Am Acad Dermatbl. 2011. 64(2):
445-7. doi: 10.1016/j,jaad.2010.08.025.
26. Rahman MH, Amin MZ, Rahman M, Satter MA. A demographic study
on vitiligo (sheti) in Bangladesh. Int J Res Med Sci. 2013; 1(2):123-8. doi:
10.5455/2320-6012.ijrms20130517.
27. Puri N, Phil M, Mojamdar M, Ramaiah A. In vitro growth characteristics of
melanocytes obtained from adult normal and vitiligo subjects.The journal
Universitas Sumatera Utara
63
of investigative dermatology. 1987; 88(4): 434-8. doi: 0022-202X/
87/$03.50.
28. Spritz RA. Six decades of vitiligo genetics: genome-wide studies provide
insights into autoimmune pathogenesis. J Invest Dermatol. 2012;132: 26873. doi: 10.1038/jid.2011.321.
29. Baum S, Barzilai A, Trau H. Vitiligo. In : Shoenfeld Y, Cervera R,
Gershwin ME, editors. Diagnostic criteria in autoimmune diseases.
Humana press [Internet]. 2008 [cited 2015 Dec 3].p. 353-8. Available from:
http://link.springer.com/ book/ 10.1007%2F978-l-60327-285-8
30. Bowcock AM, Fernandez-Vina M. Targeting skin: vitiligo and autoimm
unity. J Invest Dermatol. 2012; 132: 13-5. doi:10.103S /jid.201 1.353.
31. Wang CQF, Cruz-Inigo AE, Fuentes-Duculan J, Moussai D, Gulati N. Thl7
cells and activated dendritic cells are increased in vitiligo lesions. PLoS
One. 2011 April; 6(4): 1-11. doi: 10.1371/journal.pone.0018907
32. Rezaei N, Gavalas NG, Weetman AP, Kemp EH. Autoimmunity as an
aetiological factor in vitiligo. J Eur Acad Dermatol Venereol. 2007; 21:
865-876.doi: 10.1111/J.1468-3083.2007.02228.X.
33. Kemp EH, Emhemad S, Gawkrodger DJ, Weetman AP. Autoimmune
disorders-pathogenic aspects. Chapter 14. p. 255-78. doi: 10.5772/802
34. Haider N, Islam MS, Al-Maraf A, Shohag MH, Ali R, Rahman GKMM,
Hasnat A. Oxidative stress and antioxidant status in vitiligo patients. Dhaka
Univ J Pharm Sci. 2010 Dec; 9(2): 103-8. doi: 10.3329/dujps.v9i2.7894.
35. Naini FF, Shooshtari AV, Ebrahimi B, Molaei R. The effect of
pseudocatalase/superoxide dismutase in the treatment of vitiligo: a pilot
study. J Res Pharm Pract 2012; 1:77-80. doi: 10.4 103/2279-042X. 108375.
36. Shin JW, Nam KM, Choi HR, Huh SY, Kirn SW, Youn SW, et al.
Erythrocyte malondialdehyde and glutathione levels in vitiligo patients.
Ann Dermatol. 2010; 22(3): 279-83. doi: 10.5021/ad.2010.22.3.279.
37. Amin MZ, Rahman MH, Satter MA. Study of some biochemical
parameters of vitiligo patients in Bangladesh. Bangladesh J Sci Ind Res [
Internet]. 2012 [ cited
2015 Dec 10]; 47(2): 173-86. Available from: .
http://www.banglajol.info/index.php/BJSIR /article/view II 1449.
38. Esmaeili B, Rezaee SAR, Layegh P, Afshari JT, Dye P, Karimiani EG, et al
Expression of IL-17 and COX2 gene in peripheral blood leukocytes of
vitiligo patients. Iran J Allergy Asthma Immunol [Internet]. 2011 [cited
2015 Dec 11]; 10(2):81-9. Available from: http://www.sid.ir
/en/VEWSSID/J_pdf/943201 10202.pdf.
39. Glassman SJ. Vitiligo, reactive oxygen species and T-cells. Clin Sci. 2011;
120: 99-120.doi: 10.1042/CS20090603.
40. Kamel N, Sobhy N, Kamal H, Ismail M. A comparative study of oxidantantioxidant status in blood and tissue in vitiligo patients. EDOJ [Internet].
2010
[cited
2015 Dec 11] ;
6(2):
1-10. Available from:
http://www.edoj.org.eg/vol006/0602/002/paper.pd
Universitas Sumatera Utara
64
41. Ezzedine K, Lifn HW, Suzuki T, Katayama I, Hamzavi I, Lan CCE, et
al.Revised classification/nomenclature of vitiligo and related issues: the
vitiligo global issues consensus conference . Pigment Cell Melanoma Res.
2012 May; 25(3): El-13. doi:10.1111/j.l755-148X.2012.00997.x.
42. Faria AR, Mira MT, Tarle RG, Castro CCS, Dellatore G. Vitiligo-part2
classification, histopathology and treatment. An Bras Dermatol.
2014;89(5):784-90.doi: 10.1590/abdl806-4841.20142717.
43. Taieb A, Alomar A, Bohm M, Dell'Anna ML, PAse D, Eleftheriadou V, et
al. Guidelines for the management of vitiligo: the European dermatology
forum concencus. BJD. 2012 July; 168:5-19. doi:10.1111/j.l3652133.2012.11197.x.
44. Brazelli V, Antoninetti M, Palazzini S, Barbagallo T, De Silvestri A,
Borroni G. Critical evaluation of the variants influencing the clinical
response of vitiligo: study of 60 cases treated with ultraviolet B narrow
band phototherapy. J Eur Acad Dermatol Venereol. 2007;21:1369-74. doi:
10.1111/j.1468-3083.2007.02278.x.
45. Taieb A, Morice-Picard F, Jouary T, Ezzedine K, Cario^Andre M, Gauthier
Y. Segmental vitiligo as the possible expression of cutaneous somatic
mosaicism: implications for common non-segmental vitiligo. Pigment Cell
Melanoma Res. 2008; 21:646-52. doi: 10.1111/j. 1755-148X.2008.00511.x.
46. Hann S, Chang J, Lee H, Kim S. The classification of segmental vitiligo on
the face. Yonsei Med J [Internet]. 2000 [ cited 2015 Dec 12]; 41(2): 20912. Available from:http://www.ncbi.nlm.nih.gov/pubmed/10817021.
47. Bhor U, Pande S. Scoring systems in dermatology. Indian J Dermatol
Venereol Leprol [serial online] 2006 [cited 2015 Dec 13];72:315-21.
Available from: http://www.ijdvl. com/text.asp?2006/72/4/315/26722.
48. Taieb A, Picardo M. The definition and assessment of vitiligo: a
consensus report of the Vitiligo European Task Force. Pigment Cell
Res.2007; 20:27-35. doi: 10.1111/j.1600-0749.2006.00355.
49. Kawakami T, Hashimoto T. Disease severity indexes and treatment
evaluation criteria in vitiligo. Dermatol Res Pract. 2011; 1-3. doi: 10.1155
72011/750342.
50. Hamzavi I, Hain H, McLean D, Shapiro J, Zeng H, Lui H. Parametric
modeling of narrowband UVB phototherapy for vitiligo using a novel
quantitative
tool
the
vitiligo
area
scoring
index.
Arch
Deermatol.2004;140:677-83.
51. Al-mutairi N, Nour-Eldin O. Vitiligo treatment update. GJDV [Internet].
2003 Oct [cited 2015 Dec 14] ;10 (2): 1-13. Available from: http://www.
gulfdermaj ournal. com/pdf/2003 -10/1 .pdf.
52. Bordere AC, Lambert J, Geel NV. Current and emerging therapy for the
management of vitiligo. Clin Cosmet Investig Dermatol [Internet].
2009[cited 2015 Dec 14] ; 2: 15-25. Available from: http://www. ncbi .nlm.
nih.gov/pmc/articles/PMC3047938/.
Universitas Sumatera Utara
65
53.Felsten
L,
Alikhan
A,
Petronic-Rosic
V.
Vitiligo:A
comprehensive overview part II: Treatment options and approach to
treatment. J Am Acad Dermatol [Internet]. 2011[ cited 2015 Dec
16];65:493-514.
Available from: http://www .ncbi.nlm.
nih.gov/pubmed/21839316.
54.Gawkrodger DJ, Omerod AD, Shaw L, Mauri-sole I, Whitton ME,
Watts MJ, et al.Guideline for the diagnosis and management of vitiligo.
BJD.2008; 159: 1051-76. doi: 10.1111/j.1365-2133.2008. 08881.x
55.Clarke R. Lowering blood homocysteine with folic acid
base supplements: meta-analysis of
randomised
trials.
BMJ
[Internet].1998[cited 2015 Dec 17]; 894-8. Available from:
http://www. ncbi.nlm.nih.gov/pmc/articles/PMC28491/pdt7894.pdf.
56.Andre's E, Loukili NH, Noel E, Kaltenbach G, Abdelgheni MB, Perrin
AE, et al. Vitamin B12 (cobalamin) deficiency in elderly patients. CMAJ
[Internet]. 2004 [cited 2015 Dec 17] ; 17(3): 251-9.
Availablefrom:http://www.researchgate.net/profile/Frederic_Maloisel/publi
cation/8421627_Vitamin_B12_(cobalamin)_deficiency_in_elderly_pa
tients/links/OOb49 52289e7cc6179000000.pdf.
57.Hustad S, Ueland PM, Vollset SE, Zhang Y, Bj0rke-Monsen AL,
Schneede J. Riboflavin as a determinant of plasma total homocysteine:
effect modification by the rnethylenetetrahydrofolate reductase C677T
polymorphism. Clin Chem [ Internet]. 2000 [ cited 2015 Dec 18]; May 46
(8):
1065-71.
Available
from:
http://www
.clinchem
.
org/content/46/8/1065. Long.
58.Ubbink JB, Vermaak WJH, Merwe AVD, Becker PJ. Vitamin B12,vitamin b-6,
and
folate
nutritional
status
in
men
withhyperhomocysteinemia. Am J Clin Nutr [Internet]. 1993 [ cited 2015
Dec 19] ; 57: 47-53. Availabe from: http://ajcn. nutrition, org/
content'/57/l/47.1ong.
59. Bailey LB, Gregory JF. Folate metabolism and requirements. J. Nutr
[Internet]. 1999 [cited 2015 Dec 19]; 129: 779-82. Available from:
http://jn.nutrition.org /content/129/ 4/779. full.pdf+html.
60.Balci DD, Yunden Z, Yenin JZ, Okumus N. Serum homocysteine,
folic acid and vitamin B12 levels in vitiligo. EJD. 2009 Jul-Aug; 19 (4):
382-3. doi:10.1684/ejd.2009.0671.
61.Becatti M, Prigano F, Fiorillo, Pescitelli L, Nassi P, Lotti T, Taddei
N.The involvement of Smac/DIABLO, p53,NF-kB, and MAPK pathways
in apoptosis of keratinocytes from perilesional vitiligft skin: protective
effects of curcumin and capsaicin. Antioxidants & Redox Signaling.
2010; 13(9):1309-21. doi: 10.1089/ars.2009.2779.
62.Yu H, Chang K, Yu C, Li H, Wu M, Wu C,et al. Alterations in IL-6, IL-8,
GM-CSF, TNF-a, and IFNy release by peripheral mononuclear cells in
patients with active vitiligo. J invest Dermatol. 1997.108: 527 -9.
doi: 10.111 l/1523-1747.ep12289743.
Universitas Sumatera Utara
66
63. Utama A. Gambaran penyakit vitiligo di RSUP Haji Adam Malik Medan
tahun 2012-2014. S.Ked [Skripsi]. Medan: Universitas Sumatera Utara;
2015.
64. Rahmayanti ND, Rahmadewi. Studi Retrospektif: Profil Pasien Baru
Vitiligo
(A Retrospective Study: The Profile of New Patient with
Vitiligo). Berkala Ilmu Kesehatan Kulit dan Kelamin – Periodical of
Dermatology and Venereology. 2016 Aug; 28(2):52-8. doi:
10.20473/bikkk.V28.2.2016.52-58.
65. El-Dawela RE, Abou-elfetouh S. Relationship between homocysteine,
vitamin B12, folic acid levels and vitiligo. J. Appl. Sci. Res .2012; 8(11):
5528-35.
66. Silverberg NB. The Epidemiology of Vitiligo. Curr Derm Rep. 2015 Jan;
4:36–43.doi: 10.1007/s13671-014-0098-6.
67. Jha BN. Assessment of Prevalence of Clinical and Sociodemographic
Study of Vitiligo in Janaki Medical College, Nepal. 2016 Feb;ARJLS.
2(2):1 – 4. ISSN: 2455-3549.
68. Patil S, Gautam M, Nadkarni N, Saboo N, Godse K, Setia MS. Gender
Differences in Clinicoepidemiological Features of Vitiligo: A
CrossSectional Analysis. ISRN Dermatology. 2014 Feb;1-6. doi:
10.1155/2014/186197.
69. Elhuda. Hubungan kadar homosistei serum dengan skor vitiligo area
scoring index (VASI) . Sp.DV [ Tesis]. Padang: Universitas Andalas;
2016.
70. Battezati A, Bertoli S, Romerio AS, Testolin G. Body composition: An
important determinant of homocysteine and methionine concentrations in
healthy individuals. NMCD. 2007 Sept; 17(7): 525–34. doi:10.1016/j.num
ecd. 2006.03.006.
71. Dimitrova KR, DeGroot K, Myers AK, Kim YD. Estrogen and
homocysteine. Cardiovacres. 2002 Feb; 53:577-88. doi: 10.1016/S00086363(01)00462-X 577-588.
72. Alomari MA, Khabour OF, Gharaibeh MY, Qhatan RA .Effect of physical
activity on levels of homocysteine, folate, and vitamin B12 in the elderly.
Phys Sportsmed. 2016 Feb; 44(1):68-73. doi: 10.1080/00913847.2016.113
5037.
73. Koehler KM, Baum RG, Gary PJ, Allen RH, Stabler SP, Rimm EB.
Association of folate intake and serum homocysteine in elderly persons
according to vitamin supplementation and alcohol use. Am J Clin Nutr.
2001 March ; 73:628–37. PMID:11237942.
74. Qureshi SS, Gupta SK, Upmanyu N. A review on hyperhomocysteinemia
and its risk factors. Innovare Journal of Medical Science. 2016; 4( 2): 114. ISSN: 2321-4406.
Universitas Sumatera Utara